• No products in the cart.




CSE200: ICI Sickle Cell Disease Education Program

2nd September 2020 to 16th December 2020



Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist and Hematologist

Executive Director, International Cancer Institute

P.O. BOX 8088-30100, Eldoret-Kenya

Office: +254 718 473 446 Mobile: +254 700 522 149

Email: chiteasirwa@gmail.com or chite@intercancer.com

Web: www.intercancer.com


Goal and Objective:

The goal of the ICI_Norvatis Capacity Building Education Program for Sickle Cell Disease is to create awareness amongst healthcare professionals across all cadres in a Multidisciplinary team approach geared towards enhancing the standards of care for Sickle Cell Disease (SCD) in East Africa.

Target Audience

The primary target audience for this course comprises the multidisciplinary clinical Sickle Cell care team members including, but not limited to, physicians; fellows; residents; researchers; SCD nurse practitioners and SCD nurses; SCD pharmacists, SCD PharmTechs; SCD clinical officers; physician assistants; Laboratory scientists and technicians, and other allied health care professionals.

Learning Objectives

At the end of this educational activity (over the 16 weeks duration), participants should be able to:

  1. Describe the epidemiology, molecular basis, presentation, and natural history of SCD and the variant sickle cell syndromes.
  2. Describe the techniques for screening and the diagnosis of SCD; correctly interpret electrophoresis and HPLC traces.
  3. Understand the pathophysiology and clinical manifestations of sickle cell disease; acute pain crises and progressive organ damage.
  4. Describe the management of specific major acute complications, including acute chest syndrome, painful crisis, stroke, etc.
  5. Describe the long-term complications od SCD (including orthopaedic, ophthalmic, renal, pulmonary, endocrine, and fertility issues) and their management, in particular the need for comprehensive multidisciplinary care.
  6. Understand the use of disease-modifying agents in the management of SCD
  7. Understand gene therapy, stem cell transplant, and novel therapies in SCD treatment.
  8. Explain the appropriate use of transfusion in SCD.
  9. Describe the complications, assessment, and treatment of transfusional iron overload
  10. Demonstrate a working knowledge and practical competency for acute and chronic pain management in patients with sickle cell disease.
  11. Design a health maintenance program for Pediatrics, Adolescents, and Young Adults with SCD
  12. Understand the comprehensive Sickle Cell Disease Management guidelines.

Lecture Schedule (16 weeks)



Date CME Faculty
Sept 2nd 2020 Epidemiology, Molecular basis, Presentation and Natural History of SCD – Dr. Njuguna ICI
Sept 9th 2020 Screening and the Diagnosis of SCD ICI
Sept 16th 2020 Pathophysiology and Clinical Manifestation of SCD ICI
Sept 23rd 2020 Management of Acute Complications of SCD ICI
Sept 30th 2020 Long-term Complications of SCD and Management I ICI
Oct 7th 2020 Long-term Complications of SCD and Management II ICI
Oct 14th 2020 Disease-Modifying Agents in the Management of SCD – Prof. Chite ICI
Oct 21st 2020 Gene therapy, stem cell transplant and novel therapies in SCD treatment ICI
Oct 28th 2020 Transfusion in SCD ICI
Nov 4th 2020 Iron overload management in SCD – Chite ICI
Nov 11th 2020 Acute and Chronic pain management in patients with sickle cell disease ICI
Nov 18th 2020 Health maintenance in SCD ICI
Nov 25th 2020 Pyschosocial Issues in SCD Management ICI
Dec 2nd 2020 Case discussions in SCD management ICI
Dec 9th 2020 Improving SCD Transitions of Care: From Pediatrics to Young Adult ICI
Dec 16th 2020 Comprehensive Sickle Cell Disease Management Guidelines ICI

Course Reviews


  • 5 stars0
  • 4 stars0
  • 3 stars0
  • 2 stars0
  • 1 stars0

No Reviews found for this course.

© 2022 International Cancer Institute. All Rights Reserved